Skip to main
AMPH

Amphastar Pharma (AMPH) Stock Forecast & Price Target

Amphastar Pharma (AMPH) Analyst Ratings

Based on 6 analyst ratings
Hold
Strong Buy 17%
Buy 0%
Hold 67%
Sell 17%
Strong Sell 0%

Bulls say

Amphastar Pharma is positioned to see future success through its strong portfolio pipeline and experienced leadership with significant stock ownership. However, the company's success is dependent on the timely development and commercialization of new products, which carries a high level of risk. The significant ownership of two company directors may also pose a potential conflict of interest in corporate matters.

Bears say

Amphastar Pharma is facing challenges with their base pharmaceutical business, reflecting a decline in sales of their injectable glucagon product and generic epinephrine. Despite the recent approval of AMP-007 and the potential launch of other products, pricing pressures and competition limit their potential for significant growth. The company is also struggling with the pricing headwinds of their flagship product Baqsimi and a lack of near-term catalysts to drive growth. These factors, along with continued competition and higher R&D costs, contribute to our negative outlook on Amphastar Pharma's stock.

Amphastar Pharma (AMPH) has been analyzed by 6 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 17% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amphastar Pharma (AMPH) Forecast

Analysts have given Amphastar Pharma (AMPH) a Hold based on their latest research and market trends.

According to 6 analysts, Amphastar Pharma (AMPH) has a Hold consensus rating as of Sep 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amphastar Pharma (AMPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.